A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours

BACKGROUND: The vascular disrupting agent ombrabulin shows synergy with docetaxel in vivo. Recommended phase II doses were determined in a dose escalation study in advanced solid tumours. METHODS: Ombrabulin (30-min infusion, day 1) followed by docetaxel (1-h infusion, day 2) every 3 weeks was explo...

Full description

Saved in:
Bibliographic Details
Main Authors: Eskens, F A L M, Tresca, P, Tosi, D, Van Doorn, L, Fontaine, H, Van der Gaast, A, Veyrat-Follet, C, Oprea, C, Hospitel, M, Dieras, V
Format: Artigo
Language:Inglês
Published: Nature Publishing Group 2014
Subjects:
Clinical Study
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4007230/
https://ncbi.nlm.nih.gov/pubmed/24714750
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.137
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items